Detected ·
Signadori Bio
——
Signadori Bio has closed a €11.1M seed round extension to accelerate their in vivo engineered monocyte immunotherapy platform for solid tumours, with participation from Taiho Ventures, Sofinnova Partners, and Invivo Partners.
- Website
- www.signadoribio.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-06 08:05:51 UTC
- Signal ID
- eb572936-b6cd-4dcc-9fa8-6c167495a892
As the API returns it
{
"id": "eb572936-b6cd-4dcc-9fa8-6c167495a892",
"created_at": "2026-05-06T08:05:51.916530Z",
"company_name": "Signadori Bio",
"company_website_url": "www.signadoribio.com",
"company_linkedin_url": "https://www.linkedin.com/company/signadori-bio",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Signadori Bio has closed a €11.1M seed round extension to accelerate their in vivo engineered monocyte immunotherapy platform for solid tumours, with participation from Taiho Ventures, Sofinnova Partners, and Invivo Partners.*"
}